A. Lorenzatti

发表

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

P. Libby, P. Ridker, A. Gotto, 2008, The New England journal of medicine.

Ambulatory Patients with Cardiometabolic Disease and Without Evidence of COVID-19 During the Pandemic. The CorCOVID LATAM Study

A. Baranchuk, F. Lanas, M. Márquez, 2021, Global heart.

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

Paul M. Ridker, James T. Willerson, Robert J. Glynn, 2009 .

Cardiovascular Efficacy and Safety of Bococizumab in High‐Risk Patients

P. Ponikowski, P. Ridker, R. Glynn, 2017, The New England journal of medicine.

Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project

A. Baranchuk, J. Kaski, F. Martinez, 2021, European cardiology.

A polypill strategy to improve adherence: results from the FOCUS project.

V. Fuster, S. Pocock, Sidney C. Smith, 2014, Journal of the American College of Cardiology.

to improve adherence : results from FOCUS ( Fixed-dose Combination Drug for Secondary Cardiovascular Prevention ) Project

S. Pocock, M. Farkouh, M. Roncaglioni, 2014 .

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

P. Libby, P. Pais, J. Varigos, 2017, The Lancet.

Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial

A. Keech, R. Giugliano, M. Sabatine, 2018, JAMA cardiology.

n g l a d r n a l of m e d i c i n e Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

P. Libby, P. Pais, R. Glynn, 2017 .

The attitudes of physicians toward guideline recommendations for the management of dyslipidemia in clinical practice - The VIPFARMA ISCP Project.

A. Baranchuk, A. Lorenzatti, F. Martínez, 2022, Current problems in cardiology.

A randomized trial of rosuvastatin in the prevention of venous thromboembolism.

P. Libby, P. Ridker, A. Gotto, 2009, The New England journal of medicine.

Role of Anti-inflammatory Interventions in Coronary Artery Disease: Understanding the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).

A. Lorenzatti, M. L. Servato, 2018, European cardiology.

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

P. Libby, P. Pais, P. Ridker, 2017, The New England journal of medicine.

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential

P. Libby, P. Ridker, J. Després, 2019, Cardiovascular Diabetology.

A randomized trial of rosuvastatin in the prevention of venous thromboembolism.

P. Libby, P. Ridker, A. Gotto, 2009, The New England journal of medicine.

New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease

A. Lorenzatti, P. Toth, 2019, European cardiology.

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

Børge G Nordestgaard, Robert J Glynn, Paul M Ridker, 2009, The Lancet.

Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON

R. Rosenson, A. Lorenzatti, Huei Wang, 2021, Cardiovascular Diabetology.

Randomized study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre‐specified analysis of the Chinese population from the BERSON clinical trial

J. Ge, Yundai Chen, Zuyi Yuan, 2019, Diabetes, obesity & metabolism.

Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial

J. Ge, Yundai Chen, A. Lorenzatti, 2018, Clinical cardiology.

Atherogenic dyslipidemia in Latin America: prevalence, causes and treatment. Consensus

F. Lanas, M. Acevedo, A. Lorenzatti, 2017 .

medigraphic . org . mx Atherogenic dyslipidemia in Latin America : prevalence , causes and treatment

P. López-Jaramillo, F. Lanas, M. Acevedo, 2017 .

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

R. Collins, S. Cosgrove, P. Libby, 2017, The Lancet.

Anti-inflammatory Treatment and Cardiovascular Outcomes: Results of Clinical Trials

A. Lorenzatti, 2021, European cardiology.

Anti-inflammatory Interventions in Coronary Artery Disease

A. Lorenzatti, M. L. Servato, 2018 .

Unmet needs in the management of atherosclerotic cardiovascular disease: Is there a role for emerging anti-inflammatory interventions?

A. Lorenzatti, Brenda M Retzlaff, 2016, International journal of cardiology.

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.

N. Paynter, P. Ridker, J. Buring, 2022, The New England journal of medicine.

Clinical perspective: have the results of recent clinical trials of lipid-lowering therapies influenced the way we should practice? A Latin American perspective of current issues in clinical lipidology.

R. Santos, A. Lorenzatti, E. Escobar, 2011, Journal of clinical lipidology.

New evidence on the role of inflammation in CVD risk.

A. Lorenzatti, M. L. Servato, 2019, Current opinion in cardiology.

Considerations and Guidance for the Structure, Organisation, and Operation of Cardiometabolic Prevention Units

P. López-Jaramillo, A. Lorenzatti, Á. S. Liprandi, 2021, Global heart.

Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium

R. Santos, F. Fonseca, A. Lorenzatti, 2017, Current medical research and opinion.

Attitudes and Recommendations of Physicians towards Alcohol Consumption and Cardiovascular Health: A Perspective from Argentina

A. Baranchuk, W. Hopman, A. Lorenzatti, 2018, Diseases.

Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial

J. Ge, Yundai Chen, A. Lorenzatti, 2019, Diabetes, obesity & metabolism.

Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.

P. Libby, P. Ridker, A. Gotto, 2007, The American journal of cardiology.

Challenges in familial chylomicronemia syndrome diagnosis and management across Latin American countries: An expert panel discussion

C. Lourenço, R. Santos, J. Lima, 2021, Journal of Clinical Lipidology.

Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.

P. Ridker, R. Glynn, K. Ferdinand, 2011, American heart journal.

Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium

R. Santos, F. Fonseca, A. Lorenzatti, 2017, Current medical research and opinion.

Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention.

Deepak L. Bhatt, J. Tamargo, M. Valgimigli, 2021, International journal of cardiology.

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

P. Libby, P. Pais, J. Varigos, 2017, The Lancet.

Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial

Pedro F. Campos, Luciano Lopes de Sousa, Howard D. Rubenstein, 2023, European heart journal.